Communicating Uncertainties Associated With the Benefits and Risks of New Cancer Drugs
London School of Economics and Political Science · with Harvard Medical School / Harvard Pilgrim Health Care Institute · NCT06997185
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18+ · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Not applicable
- Target enrollment
- 3000
- US sites recruiting
- 1
- Study start
- May 9, 2025
- Record last updated
- May 30, 2025
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
This nationally representative randomized survey of US adults will evaluate the effect of using brief statements to communicate different sources of uncertainty about the benefits and harms of new cancer drugs on participants' decisions and understanding.
Being studied: Statement communicating uncertainty with a single arm trial; Statement communicating uncertainty with limited study duration; Statement communicating uncertainty with a limited study population; Statement communicating uncertainty with an unvalidated surrogate endpoint; Statement communicating uncertainty with treatment effect size
Conditions: Cancer
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Adults 18 years of age and older
- Adults fluent in English
- Adults residing in the United States
Exclusion Criteria
- Participants who do not meet each of the 3 inclusion criteria
Recruiting US locations
Harvard Medical School and Harvard Pilgrim Health Care Institute
Boston, MA 02139
Site contact: Avi Cherla · 617-201-1718 · a.j.cherla@lse.ac.uk
Study contacts (from the official record)
- Avi Cherla · 16172011718 · a.j.cherla@lse.ac.uk
Similar studies in Massachusetts
All healthy volunteers studies in Massachusetts →- RecruitingHealthy volunteersPhase 1/Phase 2
A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease
Novartis Pharmaceuticals
- Location
- Boston, MA + 7 other US sites
- Eligibility basics
- Ages 12–55
- RecruitingHealthy volunteersPhase 1
Study to Evaluate the Safety, Pharmacokinetic, and Pharmacodynamic Effects of MY006 in Healthy Volunteers and Patients With Peanut Allergy
Mabylon AG
- Location
- Boston, MA + 7 other US sites
- Eligibility basics
- Ages 12–55
- RecruitingHealthy volunteersPhase 1
Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HTX-001
Haya Therapeutics, Inc.
- Location
- Boston, MA + 1 other US site
- Eligibility basics
- Ages 18–70
- RecruitingHealthy volunteersPhase 1/Phase 2
Phase 1/2 Study of Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Vaccine Candidate in Adults 60 Years of Age and Older
Sanofi
- Location
- Boston, MA + 49 other US sites
- Eligibility basics
- Ages 60+